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Abstract
Background: Leishmania (Viannia) braziliensis is a parasite recognized as the most important etiologic agent of mucosal
leishmaniasis (ML) in the New World. In Amazonia, seven different species of Leishmania, etiologic agents of human
Cutaneous Leishmaniasis, have been described. Isolated cases of ML have been described for several different species of
Leishmania: L. (V.) panamensis, L. (V.) guyanensis and L. (L.) amazonensis.
Methodology: Leishmania species were characterized by polymerase chain reaction (PCR) of tissues taken from mucosal
biopsies of Amazonian patients who were diagnosed with ML and treated at the Tropical Medicine Foundation of Amazonas
(FMTAM) in Manaus, Amazonas state, Brazil. Samples were obtained retrospectively from the pathology laboratory and
prospectively from patients attending the aforementioned tertiary care unit.
Results: This study reports 46 cases of ML along with their geographical origin, 30 cases caused by L. (V.) braziliensis and 16
cases by L. (V.) guyanensis. This is the first record of ML cases in 16 different municipalities in the state of Amazonas and of
simultaneous detection of both species in 4 municipalities of this state. It is also the first record of ML caused by L. (V.)
guyanensis in the states of Para ´, Acre, and Rondo ˆnia and cases of ML caused by L. (V.) braziliensis in the state of Rondo ˆnia.
Conclusions/Significance: L. (V.) braziliensis is the predominant species that causes ML in the Amazon region. However,
contrary to previous studies, L. (V.) guyanensis is also a significant causative agent of ML within the region. The clinical and
epidemiological expression of ML in the Manaus region is similar to the rest of the country, although the majority of ML
cases are found south of the Amazon River.
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Introduction
Mucosal leishmaniasis (ML) in the Americas is mainly
associated with L. (V.) braziliensis, the species recognized as the
most important etiologic agent of the disease [1,2]. Marzochi and
Marzochi [3], based on the epidemiological and geographical
distribution of that same species in different ecosystems, suggested
that the human disease emerged in the Western Amazon, in
particular south of the Amazon River, where L. (V.) braziliensis is
the predominant form. Here the majority of patients with ML
typically work in areas of primary rainforest, involved in activities
related to forest product extraction [4,5]; in these cases, the
mucosal disease is the outcome of patients with a history of skin
lesions that were not treated properly. Because of this, ML is an
important public health problem and neglected disease in the
Brazilian Amazon [5,6]. L. (V.) panamensis, L. (V.) guyanensis and L.
(L.) amazonensis have also been associated with ML, but very few
cases of ML have been associated with L. (V.) guyanensis [7,8,9].
Early diagnosis and access to treatment of cutaneous leishman-
iasis (CL) are crucial to avoid the development of ML and
complications of this form of the disease, given its complexity and
severity. In an attempt to improve diagnosis, molecular techniques
such as Polymerase Chain Reaction (PCR) have been developed
for the detection of Leishmania parasites in clinical samples [10,11];
however, the low amount of DNA found in paraffin tissue hinders
the characterization of species [12]. The identification of parasite
species, today most commonly from genetic analyses, can directly
contribute to our understanding of the epidemiology of leishman-
iasis [13,14,15,16]. The aim of this study is to describe the
distribution of Leishmania species in Amazonian patients with ML
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Amazonas (FMTAM), a tertiary care unit, while taking into
consideration the geographical origin of each case.
Materials and Methods
Ethics Statement
This study was prepared in accordance with international
ethical guidelines for biomedical research involving human
subjects. The project was approved for retrospective and
prospective study; retrospective study was from July 1992 to June
2006 and prospective study from July 2006 to December 2008.
For the retrospective study, the samples (paraffin biopsies) were
obtained from an already-existing collection in the pathology
laboratory of FMTAM. For the prospective study, samples were
obtained from patients presenting to FMTAM following informed
consent, which was documented and signed.
Study Design
The study population consists of patients with ML who were
diagnosed and treated at the FMTAM in the city of Manaus,
Amazonas state, Brazil, from July 1992 to December 2006. All
patients came from the Brazilian Amazon. This region covers an
area of 5,000,000 km2, 59% of Brazil’s territory, and contains
over 775 municipalities in the states of Amazonas, Amapa ´,
Mato Grosso, Western Maranha ˜o, Para ´, Rondo ˆnia, Roraima,
Acre and Tocantins. The total population for the region has
been estimated at 20.3 million people – 68.9% of whom reside
in urban areas while the remaining 31.1% reside in rural areas
[17].
The distribution of cases was initially based on the municipality
where patients with a prior history of CL acquired their cutaneous
lesions that subsequently developed into mucosal disease. In
patients with no prior history of CL the following exposure factors
were considered to be more important than place of birth – living
within an endemic area and a history of exposure factor activities
in natural resource extraction in areas of natural forest.
DNA Preparation
The biopsied tissues were preserved in three different media: a)
formalin-fixed paraffin-embedded, b) imprint tissue on filter paper,
or c) in buffer L6 [18]. The methodology for the extraction of
DNA varied according to preservation methodology.
Embedded in paraffin. We performed 12 cuts of 20 mmi n
each block of embedded tissue using a disposable blade for each
block. The samples were deposited in 1.5 mL Eppendorf tubes.
The deparafinization was done with xilol and the DNA extraction
using the protocol of the Dneasy Blood & Tissue Kit (Quiagen).
Filter paper. The material from the filter paper was cut and
placed in sterile Eppendorf tubes. DNA was extracted using the
‘‘blood spot’’ protocol of the PureLink Genomic DNA kit
(Invitrogen).
Biopsies solution L6. Excess solution was removed by
centrifugation at 14.000 rpm. The supernatant was discarded
and the tissue was homogenized using individual disposable test
tubes (Anachem). The tissue was then processed using the DNeasy
Blood & Tissue Kit (Qiagen) as described by the manufacturer.
DNA Amplification by PCR
The presence of Leishmania DNA in tissue samples was detected
by PCR using genus-specific primer 13a and 13b [19] according to
the protocol described by Reale et al. [20].
In all tissue samples that were positive for Leishmania, PCR-
RPLF was used to identify each species present in the biopsy. PCR
was performed as described by Marfurt et al. [21]. DNA was
amplified using primers Fme and Rme. Ten ml of the PCR
products were digested with 1 U HaeIII and 1 U NcoI (New
England Biolabs) at 37uC for 2 hours and 30 minutes. The
resulting restriction fragments were separated on a 2.5% agarose
gel. The size of the fragments was estimated by comparison with a
100 bp DNA ladder and compared with positive controls for L.
(V.) braziliensis and L. (V.) guyanensis.
As positive controls for DNA extraction, all DNA samples that
did not amplify Leishmania-PCR using 13a and 13b primers were
subjected to PCR targeting 147 bp fragments of human actin
gene. The sequence of primer used was Hu_actin1_fwd 59-
CTGTGGCATCCACGAAACTA-39 and Hu_actin1_rev 59-
AGGGCAGTGATCTCCTTCTG-39. The PCR reaction was
performed in a volume of 25ml, 18.75 mlH 2O, 2.50 ml 10x buffer
containing each primer 0.3 ml, 3.5m MgCl2, 0.2 mM dNTPs and
1 U Platinum Taq DNA Polymerase (Invitrogen) 2 ml DNA
template. The PCR conditions were 5 minutes at 94uC followed
by 40 cycles of 35 seconds at 94uC, 30 seconds at 58uC and 30
seconds at 70uC, and a final extension at 70uC, 7 minutes.
Results
The reported 46 cases of ML caused by L. (V.) guyanensis and L.
(V.) braziliensis, along with their geographical origin, are depicted
in Figure 1. This is the first record of ML cases in 16 different
municipalities in the state of Amazonas and of simultaneous
detection of both species in 4 municipalities of this state. It is also
the first record of ML caused by L. (V.) guyanensis in the states of
Para ´, Acre, and Rondo ˆnia and cases of ML caused by L. (V.)
braziliensis in the state of Rondo ˆnia. Thirty eight patients had a
previous history of CL. Thirteen patients were from municipalities
located north of the Amazon River and 33 patients came from
south of the river.
Comparing the two characterized species revealed no differ-
ences concerning clinical and epidemiological aspects of cases
studied (Table 1).
Author Summary
Leishmaniasis is considered a neglected disease with 1.5
million new cases of cutaneous leishmaniasis (CL) occur-
ring each year. In the Amazon region and in the Americas
in general, ML is caused by Leishmania (Viannia) brazilien-
sis, though in rare cases it has been related to other
species. ML, which is associated with inadequate treat-
ment of CL, normally manifests itself years after the
occurrence of CL. Clinical features evolve slowly and most
often affect the nasal cavity, in some cases causing
perforation, or even destruction, of the septum. Diagnosis
is made using the Montenegro skin test, serology and
histopathology of the patients’ mucosal tissues, or by
isolation of the parasites. PCR is the best way to identify
the species of leishmaniasis and is therefore the diagnostic
method of choice. This paper describes 46 cases of ML and
their geographical origin, 30 cases associated with L. (V.)
braziliensis and 16 with L. (V.) guyanensis. The species of
leishmaniasis was identified using mucosal biopsies taken
from Amazonian patients who were diagnosed and
treated for ML in the tertiary care unit, in Manaus,
Amazonas state, Brazil. This is the highest number of ML
cases caused by L. (V.) guyanensis that has ever been
reported.
Mucosal Leishmaniasis in the Brazilian Amazon
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previous CL and the source of origin of the mucosal disease was
considered to be the same municipality where the cutaneous form
was acquired. Of the seven patients without a previous history of
CL, six lived and worked their whole lives in the same place and
only went to Manaus for treatment; the remaining patient lived in
a rural area of Manaus.
Among the 46 patients, 38 were male and 8 were female. The
average period mediating skin to mucosal disease was 17.9 years
(range: 4 months to 74 years) and the average duration of the
mucosal disease was 8.3 years (30 days to 39 years). Two of the
female patients had concomitant disease (CL/ML). Both were
pregnant at the time of acquiring CL and therefore did not treat
their skin lesions. The average age of the study population was
47.5 years (range: 16 to 80).
The PCR, performed on samples of 143 patients, was positive in
56 individuals, but in 10 samples it was not possible to characterize
the species, probably due to the low amount of DNA or a
consequence of formalin fixation and paraffin embedded tissues.
Nine patients received adequate treatment of their CL while 29
had inadequate or irregular treatment. One patient had oral
involvement alone and 45 had nasal involvement, eight of which
were associated with oral forms. 20 patients had ulcerated or
granulomatous lesions, 20 had perforated lesions, one of which
involved the palate, and six patients had infiltration. The most
frequent complaints were nasal obstruction (33/46), removal of
crusts (28/46), epistaxis (18/46), rhinorrhea (16/46) and pruritus
(16/46). The Montenegro skin test (MST) was positive in 41 cases,
negative in one and not performed in the remaining four. Direct
examination was positive in six cases, negative in 33 and not
performed in six. The histopathological examination of the
mucosal tissues was compatible with ML in 31 cases, positive in
three and inconclusive in six. Chronic rhinitis was seen in three
patients and absent in two. Serology was positive in 23 of 41
samples.
Discussion
Leishmaniasis is a disease that is increasing in the Northern
Hemisphere as a result of tourism and armed conflict in tropical
regions [22,23]. Cases of ML have been associated with multiple
species [7,8,9], but our record of cases of ML caused by L. (V.)
guyanensis is unusual. It was previously believed that the occurrence
ML caused by L. (V.) guyanensis was extremely low, with only
isolated cases having been described. The past low infection rate
described in the literature is likely to be the result of limited studies
on ML in the regions where L. (V.) guaynensis is endemic.
The geographic distribution of cases of American tegumentary
leishmaniasis indicates that L. (V.) braziliensis is the predominant
species south of the Amazon River [24], while studies in the
Figure 1. Spatial distribution of ML cases by species according to the municipality of origin.
doi:10.1371/journal.pntd.0000980.g001
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(V.) guyanensis is the most common species. In this study, 32
(71.1%) of the ML cases are from the south of the river: 22 (68.7%)
were caused by L. (V.) braziliensis and 10 (31.3%) by L. (V.)
guyanensis. North of the Amazon River, 13 (28.9%) patients were
infected: 8 (61.5%) with L. (V.) braziliensis and 5 (38.5%) with L.
(V.) guyanensis (Figure 1), which were mainly found in the Manaus
area. This data suggests that no major differences exist between
north and south of the river regarding the distribution of species
causing ML.
The association between mucosal disease and previous skin
lesions is widely accepted, as both forms can be caused by a single
species [26,27], and indeed in the 46 cases described here 37 had a
previous history of CL. In the eastern Brazilian Amazon, mucosal
disease occurs in patients with a history of previous skin lesions
that were either untreated or treated inappropriately, and which
were often caused by L. (V.) braziliensis [2,26]. The data from this
study on patient age, and the relationship between a previous
history of CL and ML, are in support of previous findings [9,28].
The current study extends this information and contributes new
data on the distribution of L. (V.) braziliensis in western Amazonia,
providing the first record of this species in 16 municipalities of
Amazonas state and an additional 12 municipalities in three other
states in the region: Acre – 1 case, Rondo ˆnia – 5 cases and Para ´–
7 cases. It is also very important to emphasize the record of 16 ML
cases caused by L. (V.) guyanensis in six different municipalities in
Amazonas state, three in Para ´, one in Rondo ˆnia and one in Acre
(Figure 1).
It is probable that ML caused by L. (V.) guyanensis has always
existed in Amazonia. We believe that this study fills a gap in
knowledge about the epidemiology of ML, rather than identifying
a change in disease pattern. Although this work has not assessed
the genetic polymorphism of L. (V.) guyanensis, this has already
been demonstrated [29,30] and others have demonstrated this
with respect to L. (V.) braziliensis [29,31,32,33]. The finding of
several hybrid genotypes of Leishmania (Viannia) in foci of
cutaneous and mucocutaneous leishmaniasis has also been
reported [34]. One cannot exclude the possibility of a genetic
polymorphism of L. (V.) guyanensis in the etiology of ML in the
Amazonian region, since little has been reported prior to this
study.
The association between inappropriately treated cutaneous
forms of the disease and the occurrence of ML appears to be
maintained for both L. (V.) guyanensis and L. (V.) braziliensis. The
association between cutaneous forms treated inappropriately and
the occurrence of the mucosal form, also in ML caused by L. (V.)
guyanensis, seems to keep the same relationship observed for the L.
(V.) braziliensis. However, it should be noted that poor access to the
diagnosis and treatment of leishmaniasis is common in the
Amazon region. This is due to the isolation of communities, with
access being almost exclusively by boat in many areas.
Furthermore, many patients lack the financial resources to stay
for long periods in Manaus to ensure adequate treatment and
follow-up. These factors may be associated with the development
of mucosal disease. The high prevalence in males in our study
population has also been observed by other authors [35,36]. The
average time of 17.6 years between the diagnosis of CL and the
appearance of ML (with one patient having a 74-yer gap between
CL and ML) recorded in this study is also in agreement with
previous findings [37,38] on the persistence of this parasite in the
host’s body and the subsequent triggering of mucosal disease.
From a clinical point of view, we would like to draw the reader’s
attention to the large number of cases – 21 (45.7%) – with nasal
perforation, which supports previous findings [27] that have
demonstrated the potential of this species to cause more severe
disease.
In summary, based on the results of this study, L. (V.) braziliensis,
which caused 2/3 of the studied cases, is the predominant species
Table 1. Clinical and epidemiological aspects of cases according to the species identified.
Category Subcategory L. (V.) braziliensis L. (V.) guyanensis
History of CL Yes 24 (80%) 15 (93.8%)
No 6 (20%) 1 (6.2%)
Location of lesions Nasal 26 (86.7%) 11 (68.8%)
Nasal/ oropharyx 3 (10%) 2 (12.5%)
Nasal/ pharynx / larynx 1 (3.33%) 2 (12.5%)
Oropharynx 0 (0%) 1 (6.2%)
Clinical presentation Infiltrated 3 (10%) 3 (18.8%)
Perforation 14 (46.7%) 6 (37.5%)
Ulcer 13 (43.3%) 7 (43.8%)
Positive 1 (3.33%) 2 (12.5%)
Histop. examination Compatible with ML 23 (7.7%) 8 (62.5%)
Inconclusive 1 (33.3%) 2 (12.5%)
Not performed 2 (6.7%) 2 (12.5%)
Non-specific chronic rhinitis 3 (10%) 2 (12.5%)
Treatment of CL Regular 4 (16.7%) 5 (31.3%)
Irregular 20 (83.3%) 10 (62.5%)
Time between CL/ML Median time (years) 16.9 14.9
Disease duration Median time (years) 12 8.6
L. (V.) braziliensis – Leishmania (Viania) braziliensisL. (V.) guyanensis –Leishmania (Viannia) guyanensis, CL-Cutaneous Leishmaniasis, Histop. Examination –
Histopathological Examination, ML – Mucosal Leishmaniasis.
doi:10.1371/journal.pntd.0000980.t001
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previous studies, L. (V.) guyanensis is also a significant causative
agent of ML in the region. The clinical and epidemiological
expression of ML in the Amazon region is similar to the rest of the
country, although the majority of ML cases are found south of the
Amazon River. ML infections are much more common in men
than in women, and men also tend to develop more severe forms
of disease with a high incidence of perforation and involvement of
structures outside of the nasal cavity.
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